Pathmanaban Omar N, Sadler Katherine V, Kamaly-Asl Ian D, King Andrew T, Rutherford Scott A, Hammerbeck-Ward Charlotte, McCabe Martin G, Kilday John-Paul, Beetz Christian, Poplawski Nicola K, Evans D Gareth, Smith Miriam J
Department of Neurosurgery, Manchester Centre for Clinical Neuroscience, Salford Royal National Health Service Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, England.
Children's Brain Tumour Research Network, Royal Manchester Children's Hospital, Centre for Paediatric, Teenage, and Young Adult Cancer, University of Manchester, Manchester, England.
JAMA Neurol. 2017 Sep 1;74(9):1123-1129. doi: 10.1001/jamaneurol.2017.1406.
Meningiomas and schwannomas are usually sporadic, isolated tumors occurring in adults older than 60 years and are rare in children and young adults. Multiple schwannomas and/or meningiomas are more frequently associated with a tumor suppressor syndrome and, accordingly, trigger genetic testing, whereas solitary tumors do not. Nevertheless, apparently sporadic tumors in young patients may herald a genetic syndrome.
To determine the frequency of the known heritable meningioma- or schwannoma-predisposing mutations in children and young adults presenting with a solitary meningioma or schwannoma.
DESIGN, SETTING, AND PARTICIPANTS: Using the database of the Manchester Centre for Genomic Medicine, this cohort study analyzed lymphocyte DNA from young individuals prospectively referred to the clinic for genetic testing between January 1, 1990, and December 31, 2016, on presentation with a single meningioma (n = 42) or schwannoma (n = 135) before age 25 years. Sequencing data were also examined from an additional 39 patients with neurofibromatosis type 2 who were retrospectively identified as having a solitary tumor before age 25 years. Patients with schwannoma were screened for NF2, SMARCB1, and LZTR1 gene mutations, while patients with meningioma were screened for NF2, SMARCB1, SMARCE1, and SUFU.
The type of underlying genetic mutation, or lack of a predisposing mutation, was associated with the presenting tumor type and subsequent development of additional tumors or other features of known schwannoma- and meningioma-predisposing syndromes.
In 2 cohorts of patients who presented with an isolated meningioma (n = 42; median [range] age, 11 [1-24] years; 22 female) or schwannoma (n = 135; median [range] age, 18 [0.2-24] years; 60 female) before age 25 years, 16 of 42 patients (38%) had a predisposing mutation to meningioma and 27 of 135 patients (20%) to schwannoma, respectively. In the solitary meningioma cohort, 34 of 63 patients (54%) had a constitutional mutation in a known meningioma predisposition gene. Twenty-five of 63 patients (40%) had a constitutional NF2 mutation, and 9 (14%) had a constitutional SMARCE1 mutation. In the cohort of those who developed a solitary schwannoma before age 25 years, 44 of 153 patients (29%) had an identifiable genetic predisposition. Twenty-four patients (55%) with a spinal schwannoma had a constitutional mutation, while only 20 (18%) with a cranial schwannoma had a constitutional predisposition (P < .001). Of 109 cranial schwannomas, 106 (97.2%) were vestibular. Four of 106 people (3.8%) with a cranial schwannoma had an LZTR1 mutation (3 were vestibular schwannomas and 1 was a nonvestibular schwannoma), and 9 (8.5%) had an NF2 mutation.
A significant proportion of young people with an apparently sporadic solitary meningioma or schwannoma had a causative predisposition mutation. This finding has important clinical implications because of the risk of additional tumors and the possibility of familial disease. Young patients presenting with a solitary meningioma or schwannoma should be referred for genetic testing.
脑膜瘤和神经鞘瘤通常是散发性的孤立肿瘤,多见于60岁以上的成年人,在儿童和年轻成年人中较为罕见。多发性神经鞘瘤和/或脑膜瘤更常与一种肿瘤抑制综合征相关,因此会引发基因检测,而孤立性肿瘤则不会。然而,年轻患者中看似散发性的肿瘤可能预示着一种遗传综合征。
确定患有孤立性脑膜瘤或神经鞘瘤的儿童和年轻成年人中已知的遗传性脑膜瘤或神经鞘瘤易感突变的频率。
设计、设置和参与者:本队列研究利用曼彻斯特基因组医学中心的数据库,分析了1990年1月1日至2016年12月31日期间前瞻性转诊至该诊所进行基因检测的年轻个体的淋巴细胞DNA,这些个体在25岁之前患有单个脑膜瘤(n = 42)或神经鞘瘤(n = 135)。还检查了另外39例2型神经纤维瘤病患者的测序数据,这些患者经回顾性鉴定在25岁之前患有孤立性肿瘤。对神经鞘瘤患者进行NF2、SMARCB1和LZTR1基因突变筛查,对脑膜瘤患者进行NF2、SMARCB1、SMARCE1和SUFU筛查。
潜在基因突变的类型,或缺乏易感突变,与所呈现的肿瘤类型以及随后其他肿瘤的发生或已知的神经鞘瘤和脑膜瘤易感综合征的其他特征相关。
在2个队列中,25岁之前患有孤立性脑膜瘤(n = 42;中位[范围]年龄,11[1 - 24]岁;22名女性)或神经鞘瘤(n = 135;中位[范围]年龄,18[0.2 - 24]岁;60名女性)的患者中,42例脑膜瘤患者中有16例(38%)有脑膜瘤易感突变,135例神经鞘瘤患者中有27例(20%)有神经鞘瘤易感突变。在孤立性脑膜瘤队列中,63例患者中有34例(54%)在已知的脑膜瘤易感基因中有胚系突变。63例患者中有25例(40%)有胚系NF2突变,9例(14%)有胚系SMARCE1突变。在25岁之前发生孤立性神经鞘瘤的队列中,153例患者中有44例(29%)有可识别的遗传易感性。24例(55%)脊髓神经鞘瘤患者有胚系突变,而只有20例(18%)颅神经鞘瘤患者有胚系易感性(P < 0.001)。在109例颅神经鞘瘤中,106例(97.2%)是前庭神经鞘瘤。106例颅神经鞘瘤患者中有4例(3.8%)有LZTR1突变(3例是前庭神经鞘瘤,1例是非前庭神经鞘瘤),9例(8.5%)有NF2突变。
相当一部分患有看似散发性孤立性脑膜瘤或神经鞘瘤的年轻人有致病性易感突变。由于存在额外肿瘤的风险和家族性疾病的可能性,这一发现具有重要的临床意义。患有孤立性脑膜瘤或神经鞘瘤的年轻患者应转诊进行基因检测。